Novo Nordisk participates in USD 57m financing round at strategic partner

Beta Bionics, a partner of both Novo Nordisk and Zealand Pharma, has closed a USD 57m series C financing round with participation from existing investors, including Novo Nordisk, and one newcomer.
Photo: Tidsvilde Stine/Ritzau Scanpix
Photo: Tidsvilde Stine/Ritzau Scanpix
by CHRISTOPHER DUE KARLSSON, translated by daniel pedersen

A partner of Danish pharmaceutical firm Novo Nordisk, US-based Beta Bionics, has been on a successful capital hunt, bringing in USD 57m in a series C financing round, the company informs in a press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading